Abstract:Kinase inhibitors are widely used in antitumor research, but there are still many problems such as drug resistance and off-target toxicity. A more suitable solution is to design a multitarget inhibitor with certain selectivity. Herein, computational and experimental studies were applied to the discovery of dual inhibitors against FGFR4 and EGFR. A quantitative structure–property relationship (QSPR) study was carried out to predict the FGFR4 and EGFR activity of a data set consisting of 843 and 5088 compounds, respectively. Four different machine learning methods including support vector machine (SVM), random forest (RF), gradient boost regression tree (GBRT), and XGBoost (XGB) were built using the most suitable features selected by the mutual information algorithm. As for FGFR4 and EGFR, SVM showed the best performance with R2test-FGFR4 = 0.80 and R2test-EGFR = 0.75, demonstrating excellent model stability, which was used to predict the activity of some compounds from an in-house database. Finally, compound 1 was selected, which exhibits inhibitory activity against FGFR4 (IC50 = 86.2 nM) and EGFR (IC50 = 83.9 nM) kinase, respectively. Furthermore, molecular docking and molecular dynamics simulations were performed to identify key amino acids for the interaction of compound 1 with FGFR4 and EGFR. In this paper, the machine-learning-based QSAR models were established and effectively applied to the discovery of dual-target inhibitors against FGFR4 and EGFR, demonstrating the great potential of machine learning strategies in dual inhibitor discovery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00652?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00652</a>.Supporting Methods: Y-randomization test (p 2). Supporting Figures: Figure S1. The relationship between Q2 and the number of descriptors for FGFR4. Figure S2. Distribution of Q2 of randomized models compared with the true model in the Y-randomization test. Figure S3. Correlograms between each important descriptor and permeability values of two activity prediction modeling: (a) FGFR4, (b) EGFR. Figure S4. Comparison of the molecular similarity between the training set and the external set: (a) FGFR4 data set, (b) EGFR data set. Figure S5. Structures of compounds 1–3. Figures S6 and S7. The chemical structures of modeling molecules of the FGFR4/EGFR activity prediction model. Figure S8. The chemical structures of 23 compounds external verification set. Figure S9. Docking results of FGFR4 and EGFR. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_001.pdf">PDF</a>)Table S1. Experimental and predicted IC50 values of FGFR4 of the whole data set that consisted of 843 compounds. Table S2. Experimental and predicted IC50 values of EGFR of the whole data set that consisted of 5088 compounds. Table S3. Detailed information for the external validation set. Table S4. Statistical analysis of 180 descriptors selected in FGFR4 activity prediction. Table S5. Statistical analysis of 280 descriptors selected in EGFR activity prediction. Table S6. Detailed information on the most essential variables for FGFR4 prediction activity modeling. Table S7. Detailed information on the most essential variables for EGFR prediction activity modeling. Table S8. The original data for cross-docking of FGFR4 and EGFR. Table S9. Residue-specific binding free energies of FGFR4 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4UXQ">4UXQ</a>) and compound 1. Table S10. Residue-specific binding free energies of EGFR (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>) and compound 1. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00652/suppl_file/ci0c00652_si_002.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations

Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Discovery of potent CSK inhibitors through integrated virtual screening and molecular dynamic simulation

Virtual screening, molecular dynamics simulations, and in vitro validation of EGFR inhibitors as breast cancer therapeutics

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

High-Throughput Empirical and Virtual Screening to Discover Novel Inhibitors of Polyploid Giant Cancer Cells in Breast Cancer

Discovery of Novel Chloropyramine-Cinnamic Acid Hybrids As Potential FAK Inhibitors for Intervention of Metastatic Triple-Negative Breast Cancer.

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Discovery of a novel Fam20C inhibitor for treatment of triple-negative breast cancer

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment

Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer

PO-462 Investigating the Potential Anti-Cancer Properties of a Novel Src Family Kinase Inhibitor in Triple Negative Breast Cancer

Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer.

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth